PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
5.19%
Revenue growth of 5.19% vs. zero growth in Healthcare. Walter Schloss might still want to see if it can translate into profits.
1.77%
Gross profit growth of 1.77% while Healthcare median is zero. Walter Schloss might see a slight advantage that could be built upon.
-21.19%
Negative EBIT growth while Healthcare median is 0.00%. Seth Klarman would check if external or internal factors caused the decline.
-22.23%
Negative operating income growth while Healthcare median is 0.00%. Seth Klarman would check if structural or cyclical issues are at play.
9.10%
Net income growth of 9.10% while Healthcare median is zero. Walter Schloss might see potential if moderate gains can keep rising.
9.10%
EPS growth of 9.10% while Healthcare median is zero. Walter Schloss might see a slight edge that could compound over time.
9.10%
Diluted EPS growth of 9.10% while Healthcare median is zero. Walter Schloss might see a slight edge that could improve over time.
-0.00%
Share reduction while Healthcare median is 0.00%. Seth Klarman would see a relative advantage if others are diluting.
-0.00%
Diluted share reduction while Healthcare median is 0.00%. Seth Klarman would see an advantage if others are still diluting.
15.38%
Dividend growth of 15.38% while Healthcare median is flat. Walter Schloss might appreciate at least a modest improvement.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
145.37%
10Y CAGR of 145.37% while Healthcare median is zero. Walter Schloss might see a slight advantage that can compound over very long horizons.
35.19%
5Y CAGR of 35.19% while Healthcare is zero. Walter Schloss might see a slight improvement that could compound if momentum builds.
31.75%
3Y CAGR of 31.75% while Healthcare median is zero. Walter Schloss might see a modest improvement overshadowing the broader sector’s stagnation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
144.02%
Net income/share CAGR exceeding 1.5x Healthcare median of 37.30% over a decade. Joel Greenblatt might see a standout compounder of earnings.
19.91%
5Y net income/share CAGR 50-75% of Healthcare median. Guy Spier might question fundamental disadvantages in cost structure or growth drivers.
28.78%
3Y net income/share CAGR near Healthcare median. Charlie Munger sees standard sector-level performance in the last few years.
295.46%
Equity/share CAGR exceeding 1.5x Healthcare median of 28.19% over 10 years. Joel Greenblatt would see if a high ROE underlies this compounding advantage.
76.61%
5Y equity/share CAGR > 1.5x Healthcare median of 13.34%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
35.05%
Positive short-term equity/share CAGR while Healthcare is negative. Peter Lynch finds a relative advantage vs. sector-level slowdown.
361.54%
Dividend/share CAGR of 361.54% while Healthcare is zero. Walter Schloss sees a minor improvement that could compound if the firm maintains consistent raises.
150.00%
5Y dividend/share CAGR of 150.00% while Healthcare is zero. Walter Schloss sees at least some improvement that could compound over time.
87.50%
3Y dividend/share CAGR of 87.50% while Healthcare is zero. Walter Schloss sees a slight advantage if the firm is at least inching up payouts.
1721.43%
AR growth of 1721.43% while Healthcare median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
4.84%
Inventory growth of 4.84% while Healthcare median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
10.68%
We expand assets while Healthcare is negative. Peter Lynch sees a possible advantage if expansions align with profitable markets or a recovering cycle.
3.47%
Positive BV/share change while Healthcare median is negative. Peter Lynch finds a strong advantage vs. peers failing to expand equity.
75.11%
Debt growth of 75.11% while Healthcare median is zero. Walter Schloss might see a modest difference that matters if interest coverage is tight.
No Data
No Data available this quarter, please select a different quarter.
8.24%
SG&A growth far above Healthcare median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.